Kairos Pharma, Ltd.(KAPA) - 2024 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 46-2993314 (State or other jurisdiction of incorporation or organization) (I.R.S Employer Identification No.) Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share KAPA NYSE American FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT ...